You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: BIOLYTIC LAB PERFORMANCE, INC. Topic: 300
Summary RNA synthesis technologies have become critical in basic biomedical research and in development of RNA based sensors diagnostics and therapeutics Currently RNAs are synthesized by either solid phase phosphoramidite chemistry or by transcription in solution with phage encoded RNA polymerases The structural diversity of chemically synthesized RNAs is limited by the availa ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: FasCure Therapeutics LLC Topic: 102
DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: CytoInformatics LLC Topic: NIA
DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Novici Biotech LLC Topic: NHLBI
DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: PROFUSA, INC. Topic: NHLBI
DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: iXpressGenes, Inc. Topic: 100
Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Rimedion, Inc. Topic: NHLBI
DESCRIPTIONprovided by applicantIn this Phase II STTR application Rimedion seeks to commercialize a novel treatment for patients suffering from Fanconi anemia and request funding for a Phase I II clinical trialThe product will utilize a HIVbased lentiviral vector expressin the Fanconi anemia A proteinThe strong scientific support for this approached is strengthened by a successful Phase I STTRThe ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: ZMK Medical Technologies, Inc. Topic: 102
This Phase II proposal is a continuation of our successful Phase I grant whose overarching goal is to develop a more robust and accurate method for the deformable fusion of pre operative magnetic resonance images MRI and intra procedure trans rectal ultrasound TRUS images to guide prostate biopsy Prostate cancer is a major cause of death in the U S and biopsy is the gold standard for its dia ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: ARRHYTHMOTECH Topic: NIDA
DESCRIPTION provided by applicant The objective of this Phase II STTR grant application is to continue the R Randamp D efforts initiated in Phase I The long term objective for Arrhythmotech is to develop and market an instrument for the simultaneous recording of sympathetic nerve activity SNA and electrocardiogram ECG using electrodes on the skin This method neuECG was discovered in Dr ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: PROVAIDYA Topic: NIA
DESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health